Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Effect of Mediterranean Diet Combined With Intermittent Fasting on Liver Fibrosis Compared to Naltrexone/Bupropion in People With Cardiometabolic Risk Factors

NCT06845345 is registered in ClinicalTrials.gov with Carmen Dietvorst as lead sponsor.

NCT NCT06845345
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06845345 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Effect of Mediterranean Diet Combined With Intermittent Fasting on Liver Fibrosis Compared to Naltrexone/Bupropion in People With Cardiometabolic Risk Factors
Lead sponsor
Carmen Dietvorst
Phase
Phase 4
Overall status
Enrolling by invitation
Start date
April 14, 2025
Completion date
July 31, 2027
Enrollment
70 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

cardio-metabolic health, cardio-metabolic risk, diabetes mellitus, type 2, dyslipidaemia, hepatic fibrosis, hepatic steatosis, hypertension, liver fibrosis, liver steatoses, masld, masld - metabolic dysfunction-associated steatotic liver disease, overweight or obesity